Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Periplaneta americana aqueous extract fraction >10 kDa, also designated as PAW3, is a biologic fraction derived from the American cockroach (*Periplaneta americana* L.). This fraction is isolated through membrane ultrafiltration of aqueous extracts from dried cockroach powder, specifically retaining components with molecular weights exceeding 10 kDa, such as proteins, polypeptides, and polysaccharides. It has been investigated for its therapeutic potential in treating ulcerative colitis (UC), where it has demonstrated the ability to ameliorate colonic inflammation, preserve intestinal barrier integrity, and modulate gut microbiota dysbiosis in preclinical models. While the unfractionated extract is the basis for approved pharmaceutical products in China (e.g., Kangfuxin), the >10 kDa fraction is currently a research-stage compound used to identify the specific active constituents responsible for the extract's medicinal properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on periplaneta americana aqueous extract fraction >10 kDa.